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Introduction
Age-related macular degeneration
(AMD) is the most frequent cause of
blindness among individuals ‡55 years
in developed countries (Leibowitz
et al. 1980; Attebo et al. 1996; Fried-
man et al. 2004), and with increasing
longevity, the incidence of AMD is ris-
ing. The therapeutic options for AMD
are limited, though improving, in parti-
cular for neovascular AMD. (Ciulla
et al. 1988; Macular Photocoagulation
Study Group 1993; Avery et al. 2006).
Although vision loss with neovascular
AMD is more sudden and severe, the
non-neovascular forms, including the
atrophic type, are more prevalent and
account for approximately 90% of
cases (Richer et al. 2004). At present,
there is no consensus with respect to
the management (including risk analy-
sis and ⁄or prevention) of these more
common non-neovascular forms of the
condition, which may, at least partly,
reflect our incomplete understanding of
AMD’s aetiopathogenesis.
In the absence of effective treatment
strategies for non-neovascular AMD,
interest has focused on prevention
and ⁄or retardation of progression.
Macular pigment (MP), composed of
lutein (L) and zeaxanthin (Z), two hy-
droxycarotenoids, which are entirely
of dietary origin (Bone et al. 1997;
Johnson et al. 2005) and the retinal
metabolite of L; meso-Zeaxanthin
(meso-Z), is believed to be associated
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ABSTRACT.
Purpose: Of the antioxidants found in the human retina, only the macular carot-
enoid quantities can be estimated noninvasively (albeit in a collective fashion),
thus facilitating study of their role in that tissue. The aim of this study was to
evaluate concordance between macular pigment optical density (MPOD) values
recorded on a commercially available instrument, the MPS 9000, with those of
an already validated heterochromatic flicker photometry instrument. Also, we
assessed and compared test–retest variability for each instrument.
Methods: Macular pigment optical density at 0.5 retinal eccentricity was mea-
sured using two different heterochromatic flicker photometers, the MPS 9000
and the Macular DensitometerTM, in 39 healthy subjects. Test–retest variabil-
ity was evaluated separately for each instrument by taking three readings over
a 1-week period in 25 subjects.
Results: There was a moderate positive correlation for MPOD at 0.5 of reti-
nal eccentricity between the MPS 9000 and the Macular Densitometer
described by the linear equation y = 0.763x + 0.172 (r = 0.68, p < 0.001,
r2 = 0.46); however, a paired-samples t-test showed a significant difference in
terms of mean values, with a bias of lower MPOD values being yielded by the
MPS 9000 (t = )4.103, p < 0.001). Bland–Altman analysis indicated only
moderate agreement between the two instruments, reflected in 95% limits of
agreement of 0.1 ± 0.27. Inter-sessional repeatability, expressed as a coeffi-
cient of repeatability, ranged from 0.18 to 0.21 [mean (±SD): 0.19 (0.02)] for
the MPS 9000 and from 0.11 to 0.12 [mean (±SD): 0.12 (0.01)] for the Mac-
ular Densitometer.
Conclusion: The results demonstrate that the MPS 9000 consistently yields
MPOD readings, which are lower than that found with the Macular Densi-
tometer, and exhibits substantial test–retest variability.
Key words: age-related macular degeneration – heterochromatic flicker photometry – Macular
Densitometer – macular pigment – MPS 9000
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with reduced risk of development and
progression of AMD. Macular pig-
ment can be augmented, not only by
eating food rich in these carotenoids,
such as spinach, but also by dietary
fortification with one of the many
commercially available food supple-
ments (Bone et al. 2003; Connolly
et al. 2010). Epidemiological studies
have observed an inverse association
between the prevalence of AMD and
a diet rich in L and Z (Eye Disease
Case-Control Study Group 1993; Sed-
don et al. 1994), and furthermore,
eyes with AMD have typically been
shown to exhibit significantly lower
levels of MP when compared to those
without AMD (Eye Disease Case-
Control Study Group 1993; Beatty
et al. 2001; Bone et al. 2001; Bernstein
et al. 2010), although this relationship
was not observed in the Muenster
Aging and Retina Study (Dietzel et al.
2011).
The putative capacity of MP to play
a role in preventing or retarding the
progression of AMD rests on its abil-
ity to limit photo-oxidative injury in
the inner retina through its prerecep-
toral absorption of short wavelength
light (Snodderly et al. 1984a,b; Snod-
derly 1995) and ⁄or the antioxidant
properties of these carotenoids as they
act as free radical scavengers in the
retina (Snodderly 1995). The optical
density and spatial distribution of MP
have been shown to vary dramatically
between individuals (Pease et al. 1987;
Bone et al. 1992; Hammond et al.
1995), with consequential large inter-
individual variation in prereceptoral
short wavelength light absorption and
antioxidant activity in the retina.
Several methods for measuring the
optical density of MP have been
developed, thereby enabling investiga-
tors and ⁄or eye care professionals to
detect changes in MP concentration
and distribution over time and there-
fore monitor the response to dietary
modification or fortification. Unsur-
prisingly, there is a growing demand
for a valid, reproducible, user-friendly
instrument that measures macular pig-
ment optical density (MPOD).
Heterochromatic flicker photometry
(HFP) was the first, and remains the
most widely used, technique for mea-
suring MPOD in vivo (Snodderly et al.
1984a,b; Pease et al. 1987; Hammond
et al. 1997, 2005; Berendschot et al.
2003; Nolan et al. 2008; Rougier et al.
2008; Stringham et al. 2008). Hetero-
chromatic flicker photometry is a psy-
chophysical method, which requires
the subject to make iso-luminance
matches between green (not absorbed
by MP) and blue (strongly absorbed
by MP) flickering lights, which is typi-
cally perceived as the point of cessa-
tion (or detection) of flicker. The
technique typically employs a stimu-
lus-surround configuration, where the
stimulus consists of a target presented
in counterphase flicker (alternating
blue to green). The log ratio of the
amount of blue light absorbed cen-
trally, where MP peaks, to that
absorbed at a peripheral retinal locus
gives a measure of the individual’s
MPOD. This method has been vali-
dated against the absorption spectrum
of MP in vitro (Bone et al. 1992;
Hammond et al. 2005). The MPS
9000 is a relatively new HFP instru-
ment that has been developed for clin-
ical use (van der Veen et al. 2009). It
is evident from the literature, how-
ever, that while based on the same
basic optical principles of HFP, signif-
icant design and methodological dif-
ferences do exist. We report a
concordance study between the newly
available commercial instrument, the
MPS 9000, and the validated and con-
ventional research instrument for mea-
suring MPOD, the Macular
Densitometer. We also measured and
compared the inter-sessional repeat-
ability for the two instruments.
Materials and Methods
This study was conducted at Dublin
Institute of Technology (DIT), Dub-
lin, Republic of Ireland. Eighty-nine
subjects, aged 21–61 years, were
recruited by word of mouth and were
randomly assigned to either the con-
cordance [39 subjects; mean age 29
(±11)] or repeatability [50 subjects;
mean age 34 (±10)] arms of the
study. Informed consent was obtained
from each volunteer after the provi-
sion of a detailed information sheet.
Ethical approval was granted by the
research ethics committee at DIT, and
the experimental procedures adhered
to the Declaration of Helsinki. Inclu-
sion criteria required participants to
be aged 18 years or older, have no
clinical signs of ocular pathology and
have logMAR visual acuity (VA) of
better than 0.2 in the study eye. All
subjects were naı¨ve to both the instru-
ments and to the process of measure-
ment of MP.
The study eye was selected on the
basis of corrected distance visual acuity
(CDVA); the eye with the better CDVA
being selected, and in cases of equal
CDVA, the dominant eye was selected.
A computer-generated LogMAR test
chart (Test Chart 2000 Pro; Thompson
Software Solutions, 74 Pine Grove,
Hatfield, AL97BW, UK) was used to
determine CDVA at a viewing distance
of 4 m, using a Sloan ETDRS letterset.
Subjects were requested to wear non-
tinted normal distance correction spec-
tacles, if required. An ocular health
examination was conducted to rule out
any ocular pathology.
Macular pigment optical density was
measured at 0.5 eccentricity on each
instrument, on the same day, in 39
subjects to determine instrument con-
cordance. To assess test–retest vari-
ability for each instrument, 25 subjects
had MPOD measured on three occa-
sions over a 1-week period on each
instrument, 50 subjects were recruited
for this part of the investigation, 25
were randomly assigned to the MPS
9000 and 25 were randomly assigned
to the Macular Densitometer. All data
were collected by a single operator.
The instruments used in this study
were the MPS 9000, (Tinsley Precision
Instruments Ltd, Croyden, Essex,
UK), and the Macular Densitometer
(Macular Metrics II, Rehoboth, MA,
USA). The instrument used first in the
concordance arm of the study was
randomly selected on a case-by-case
basis to minimize the risk of introduc-
ing bias attributable to a learning or
fatigue effect from either instrument.
MPS 9000
(M|POD ⁄QuantifEYE)
The MPS 9000 is a small, portable
HFP instrument, capable of measur-
ing MPOD at a single retinal locus
(0.5 retinal eccentricity). The instru-
ment uses a foveal target of 1 diame-
ter (edge located at 0.5 retinal
eccentricity) with the reference loca-
tion at 8 retinal eccentricity (van der
Veen et al. 2009). Testing was carried
out according to the manufacturer’s
instructions. Prior to the first session,
a short practice test was carried out
to familiarize the participant with the
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technique. Once the subject success-
fully completed the practice run, the
subject’s sensitivity to flicker was
determined by a built in pretest rou-
tine, which enabled the appropriate
initial luminance contrast of the two
light sources to be established. This
short (30 seconds) pretest flicker sensi-
tivity routine was used to ensure the
participants were in the middle of
their flicker sensitivity range when
performing the main task, as flicker
sensitivity varies between individuals.
During the main test, the frequency
of the blue (465 nm) and green
(530 nm) light sources were automati-
cally ramped down from 55 Hz for a
series of luminance ratios of the two
light sources. Initially, the observer
viewed the target centrally and pressed
a button when flicker was detected.
This sequence of obtaining a flicker
threshold for each blue-to-green ratio
continued until a flicker response
curve was obtained, where the mini-
mum represents the equalization of
the blue and green luminance. The
procedure of obtaining the flicker
detection for a series of blue-to-green
ratios was repeated, after an addi-
tional short practice run, for periph-
eral viewing, with the subject fixating
a red disc at a reference point of 8
horizontal eccentricity. The central
and peripheral minima were used to
calculate MPOD. The formation of
the central and peripheral flicker
response curves was monitored by the
experienced examiner throughout the
course of the examination to ensure
reliability of the results based on the
formation of a characteristic curve
shape. Macular pigment optical den-
sity was calculated on the basis of a
single, reliable measurement using
both the central and peripheral stim-
uli. If a reliable measurement could
not be obtained, the subject was re-
instructed and afforded one additional
and immediate opportunity to provide
a reliable result. Failure to achieve a
reliable result within two such mea-
surement cycles resulted in exclusion
from the study.
Macular Densitometer
The Macular Densitometer is a vali-
dated MPOD measurement instru-
ment capable of determining a spatial
profile of MP, by the measurement of
MPOD at various retinal eccentricities
between 0.25 and 3 (Wooten et al.
1999). For the purpose of this study,
readings were taken centrally at 0.50
using a 1 disc, [commonly used as it
has been shown to have the highest
repeatability of results (Snodderly
et al. 2004)], matching that used in the
MPS 9000, and a reference location at
7 using a 2 target (van der Veen
et al. 2009). The Macular Densitome-
ter was calibrated daily, and testing
was carried out according to the man-
ufacturer’s instructions.
Prior to using the Densitometer, all
subjects were shown an explanatory
video describing the method for
recording null flicker matches. The
subject’s critical flicker frequency
(CFF) was then measured, and the
optimal flicker frequency (OFF) deter-
mined using a defined test algorithm
designed to minimize variance
between readings, in a process that
has become known as customized
HFP. If a subject could not reach null
flicker, the investigator increased the
flicker frequency in increments of
1 Hz, until null flicker was perceived.
Alternatively, if a subject exhibited a
wide variation in null flicker readings
(>10% of mean radiance at null
flicker), the flicker frequency was
decreased in increments of 1 Hz, until
an acceptable null flicker range was
achieved. An acceptable null flicker
range was defined as one where the
null flicker radiance values achieved
by the subject were within 5% of the
mean null flicker radiance at that test
locus. Once the OFF was determined,
the subject was required to find the
middle zone of no flicker by turning a
dial that adjusts the ratio of blue
(458 nm) to green (530 nm). The
desired end-point when using the Den-
sitometer was a point of zero or ‘null’
flicker. For a detailed description of
each instrument and instructions for
use, please refer to van der Veen et al.
(2009) and Wooten et al. (1999).
Statistical analysis
The statistical software package spss
18.0 for windows was used for data
analysis. Mean MPOD for the MPS
9000 and the Macular Densitometer
was compared using paired-samples
t test. Bland–Altman analysis and
plots, as well as the limits of agree-
ment, were used to quantify the agree-
ment between the two instruments.
Inter-sessional repeatability is
expressed as a coefficient of repeat-
ability, which was calculated as the
standard deviation of the mean differ-
ence between measurements, and mul-
tiplied by 1.96. Coefficients of
repeatability were calculated for (visit
1–visit 2), (visit 2–visit 3) and (visit
1–visit 3) for each instrument. A one-
way repeated measures anova was
conducted to test for a learning or
fatigue effect that might confound the
test–retest analysis.
Results
The data were analysed (i) to compare
measurements taken at 0.5 on the two
instruments and (ii) to assess inter-ses-
sional repeatability of each instrument.
Two subjects were excluded from the
instrument concordance analysis, and
one subject from the instrument inter-
sessional repeatability analysis, on the
basis that they were deemed unable to
perform the MPS 9000 task satisfacto-
rily on the initial or repeat assess-
ments. Data analysis is conducted and
presented for the remaining 37 subjects
in the concordance analysis, and 49
subjects in the inter-sessional repeat-
ability analysis.
Instrument concordance
A scatterplot, graphically representing
the relationship between MPOD val-
ues at 0.5 eccentricity obtained with
each instrument, is shown in Fig. 1
(r = 0.68, p < 0.001).
A paired-samples t-test comparing
the mean MPOD, as measured on
each instrument, yielded a statistically
significant difference between instru-
ments (t = )4.103, p < 0.001), dem-
onstrating a bias of lower MPOD
values obtained on the MPS 9000,
reflected in an average difference in
MPOD values of 0.1 log unit between
the two instruments (Fig. 2). The 95%
limits of agreement between instru-
ments were 0.1 ± 0.27.
Inter-sessional repeatability
A one-way repeated measures anova
was conducted to assess repeat
MPOD measurements for a learning
or fatigue effect for each instrument.
Mauchly’s test of sphericity was not
significant (p > 0.05) for either
instrument. There was no significant
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difference in repeat MPOD measure-
ments for either the MPS 9000 or the
Macular Densitometer, indicating the
absence of any learning or fatigue
effect [MPS 9000 (F = 0.09, p =
0.92); Macular Densitometer (F =
2.556, p = 0.09)]. Given that the
p value for the Macular Densitometer is
close to significance, a post hoc paired-
samples t test was conducted comparing
visit 1 and visit 3. No significant differ-
ence between the initial and final mea-
surements was observed (t = 0.000,
p = 0.999), providing further reassur-
ance of the absence of a meaningful
learning effect using this device.
A Bland–Altman plot was con-
structed to assess agreement between
repeat measures taken on the MPS
9000 (Fig. 3). The coefficient of
repeatability for the MPS 9000 ranged
from 0.18 to 0.21 (mean 0.19 ± 0.02;
see Table 1).
A Bland–Altman plot was also con-
structed to assess agreement between
repeat measures taken on the Densi-
tometer (Fig. 4). The coefficient of
repeatability for the Macular Densi-
tometer ranged from 0.11 to 0.12
(mean 0.12 ± 0.01; see Table 1).
Inter-sessional repeatability results for
each instrument are presented in
Table 1.
Discussion
The Macular Densitometer has been
validated in previous studies (Wooten
et al. 1999; Snodderly et al. 2004;
Stringham et al. 2008), and the HFP
technique for measuring MPOD has
also been validated against the
absorption spectrum of MP in vitro
(Bone et al. 1992; Hammond et al.
2005). The MPS 9000 is a new com-
mercial technology designed to mea-
sure MPOD and employs the HFP
technique. Despite the use of HFP,
the validity of this novel instrument
has yet to be determined, and as such,
the current study, which assesses the
accuracy and repeatability of this new
commercial instrument in relation to
the current research standard HFP
instrument, the Macular Densitometer
is timely and necessary.
In the current study, mean MPOD
was 0.32 (±0.15) for the MPS 9000
and 0.42 (±0.18) for the Macular
Densitometer, values that are consis-
tent with previous studies (Ciulla et al.
2001; Snodderly et al. 2004; Loane
et al. 2007; Nolan et al. 2008; Makri-
daki et al. 2009; Bartlett et al. 2010;
Loughman et al. 2010). The correla-
tion between the MPS 9000 and the
Macular Densitometer in this study
was found to be positive, statistically
significant, and similar to that previ-
ously reported comparing the MPS
9000 to the Macular Pigment Reflec-
tometer (van der Veen et al. 2009).
However, the mean difference between
instruments was statistically signifi-
cant, with a bias of lower MPOD in
association with the MPS 9000,
reflected in 95% limits of agreement
of 0.1 ± 0.27, indicating only moder-
ate agreement between the two sets of
readings (Bland & Altman 1986). The
underestimation in MPOD values
yielded by the MPS 9000 is in the
range 0.05–0.15, but only in
approximately 36% of subjects, with
differences between respective mea-
surements ranging from 0.35 to )0.3,
a 0.65 log unit range. It should be
pointed out however that there are a
number of exceptions to the trend for
lower MPOD values on the MPS 9000
compared with the Macular Densi-
tometer. In five subjects, the MPS
9000 demonstrated higher MPOD val-
ues when compared to the Macular
Densitometer (see Fig. 1), and in two
of these cases, the difference is sub-
stantial (0.26 and 0.30, respectively).
Clinically, these two cases could not
be discarded as both subjects were
deemed to have understood and per-
0
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Fig. 1. Relationship between macular pigment optical density readings at 0.5 retinal eccentric-
ity obtained with each instrument, with the line y = x superimposed.
Fig. 2. Bland–Altman plot for macular pigment optical density values at 0.5 retinal eccentric-
ity, showing 95% limits of agreement between the MPS 9000 and Macular Densitometer.
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formed the MPOD measurement to an
acceptable standard on both devices.
From a statistical viewpoint however,
these may be regarded as outliers. Re-
analysis of the data excluding these
two cases does improve the observed
correlation and agreement between
devices to more acceptable levels
(r = 0.778, and the coefficient of
repeatability = 0.20). In other words,
and contrary to the observations of
van der Veen et al. (2009), the observed
discrepancy between instruments is not
systematic and is therefore not amena-
ble to adjustment by means of a correc-
tion factor.
Inter-sessional repeatability is an
important consideration for any pro-
spective MP measurement device. The
test–retest variability of the Macular
Densitometer and the MPS 9000 has
been investigated previously (Snodder-
ly et al. 2004; Gallaher et al. 2007;
van der Veen et al. 2009; Bartlett
et al. 2010; De Kinkelder et al. 2011).
The Macular Densitometer has been
shown to demonstrate good test–retest
and intraclass correlation, with a coef-
ficient of variation ranging from 17 to
22% (Snodderly et al. 2004; Gallaher
et al. 2007). The MPS 9000 has also
been reported to exhibit good repeat-
ability, with limits of agreement rang-
ing from 0.15 to 0.18 (van der Veen
et al. 2009; De Kinkelder et al. 2011),
but these results could not be
substantiated in a recent study, which
reported coefficients of repeatability
and reproducibility ranging from 0.25
to 0.33 (Bartlett et al. 2010). The
observed discordance between studies
might be explained, at least in part,
by methodological differences, includ-
ing the use of more robust, averaged
data in the research setting of the for-
mer study (van der Veen et al. 2009),
when compared with data collected in
a manner more reflective of a typical
clinical setting in the latter study
(Bartlett et al. 2010).
The mean coefficient of repeatabil-
ity for the MPS 9000 in the current
study was 0.19 (±0.02), and ranged
from 0.18 to 0.21, which is consistent
with previous findings (van der Veen
et al. 2009; De Kinkelder et al. 2011),
and has significantly better repeatabil-
ity than that determined by Bartlett
et al. (2010), whose interpretation of
results is somewhat problematic, and
simply not scientifically justified or
sustainable. They do, nonetheless, still
suggest a substantial amount of vari-
ability between sessions of MPOD
measurement. For the purposes of
comparability, the repeatability of the
Macular Densitometer was also
assessed. The mean coefficient of
repeatability for the Macular Densi-
tometer was 0.12 (±0.01) and ranged
from 0.11 to 0.12, substantially better
than the MPS 9000. Indeed, the range
of MPOD values across all three mea-
sures was <0.1 for 92% of subjects
and <0.05 for 44% of subjects, using
the Macular Densitometer, and this
compares with only 54% and 25%,
respectively, for the MPS 9000.
The MPS 9000 device is not
described in sufficient detail in the
published literature to provide a com-
prehensive analysis of the potential
reasons for the inter-instrument
observed differences in MPOD. Some
of the design features of the instru-
ment could potentially explain the
observed differences. It is not clear,
for example, whether a correction fac-
tor has been applied to account for
differences in the spectral output of
the chosen LEDs compared with the
absorption spectrum of MP. The blue
LED peak output for the MPS 9000
is given as 465 nm (van der Veen
et al. 2009, De Kinkelder et al. 2011),
although it is listed as 470 nm in the
product literature. This compares to
MP peak absorption at 458 nm, which
matches the LED output employed in
the Macular Densitometer. If such a
correction factor has been employed
for the MPS 9000, it is not clear
whether this correction is based on
LED manufacturer provided spectral
Table 1. Inter-sessional MPOD variability (mean ± SD) and coefficient of repeatability for the MPS 9000 and Macular Densitometer.
Instrument
Mean (±SD) MPOD Coefficient of repeatability
Visit 1 Visit 2 Visit 3 Visit 1–visit 2 Visit 2–visit 3 Visit 1–visit 3
MPS 9000 0.31 (±0.15) 0.32 (±0.16) 0.32 (±0.17) 0.18 0.21 0.18
Macular Densitometer 0.40 (±0.15) 0.38 (±0.16) 0.40 (±0.16) 0.11 0.12 0.12
MPOD, macular pigment optical density.
Fig. 3. Bland–Altman plot showing 95% limits of agreement for repeat measures at visit 2 and
visit 3 for the MPS 9000.
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outputs or independent spectral analy-
sis of the specific LED outputs, which
would be preferred. If this correction
has not been applied or has been
incorrectly applied, it certainly could
explain the difference in MP optical
density values derived by the two
devices. Aside from the above
unknown characteristics of the MPS
9000, there are a number of significant
differences between the devices and
the respective methodologies, which
may explain both the observed lack of
concordance and the disparity in
terms of inter-sessional repeatability.
The MPS 9000 employs a 1 stimu-
lus for both the central and peripheral
measurements, whereas the Macular
Densitometer employs a 2 stimulus
for the peripheral measurement only
and a 1 target centrally. Invariably,
subjects reported difficulty completing
the peripheral measurement, when
using the MPS 9000, whereas no such
difficulty was reported for the Macu-
lar Densitometer. It is likely that this
difference in peripheral stimulus size is
contributing to the greater relative dif-
ficulty experienced by subjects using
the MPS 9000 and may explain the
exclusion of three subjects unable to
complete the peripheral measurement
using this instrument. The difference
in eccentricity of the peripheral
reference target (7 for the Macular
Densitometer and 8 for the MPS
9000) could be a potential source of
differences in the derived MP values
(as the calculation of MP is based on
the log ratio of central versus refer-
ence values). As the MPS 9000
employs a more eccentric reference
stimulus, it might be expected that
this technique would consequently
derive higher MP values, if the effect
was significant. The MPS 9000, how-
ever, appears to underestimate MPOD
in comparison with the Macular Den-
sitometer, so it is unlikely that the dif-
ference in reference location can
explain the mean difference between
devices.
Another distinction between the
two instruments rests on the role of
subject performance. The Macular
Densitometer affords significant con-
trol to the subject, who can adjust the
ratio of blue to green until a null
flicker sensation is achieved, without a
time restriction. The subject is simply
instructed to use a method of adjust-
ment or bracketing method to define
the null flicker zone. The MPS 9000
employs a different technique, where a
suprathreshold flicker rate is gradually
reduced at a set rate of 6 Hz per sec-
ond, and the subject responds by
pressing a button to indicate the point
at which flicker is detected. The rate
of flicker decrease is a compromise
between testing time and differences
in subject reaction times (van der
Veen et al. 2009). Although reaction
times are known to vary little across
age (Porciatti et al. 1999), response
times are significantly more complex.
It would seem reasonable to suggest
that subject threshold criteria could
change during the course of a mea-
surement session, particularly as task
complexity increases from the central
to peripheral target testing (Madden
& Allen 1995; Hommel et al. 2004).
Such a change in response criterion
might not be easily detected by the
examiner and could contribute to
poor results.
Further, the MPS 9000 is unable to
provide a useful measure of subject
performance reliability. The only per-
formance check an examiner can use
is to determine that a ‘typical’
V-shaped flicker response curve is gen-
erated. The product literature
describes that ‘irregularities in the
data’ are typical and that the shape of
the curves can vary between individu-
als. This makes interpretation of the
curve, and reliability of the result,
therefore dependent on examiner skill
and training and subject to significant
variation. Indeed, such dependency
could represent a partial explanation
for the poor coefficient of repeatabil-
ity reported by Bartlett et al. (2010).
It has been suggested that the number
of subjects in the Bartlett paper with
significant variation in test–retest
MPOD values represents operator
error (inappropriate acceptance of
low-quality V-shaped flicker response
functions), rather than measurement
noise (Murray et al. 2011). This may
be the case, but if so, this reinforces
the observations herein that MPOD
values obtained using the MPS 9000,
may well be significantly affected by
examiner skill level and training, and
furthermore, that the limited means to
determine patient performance accept-
ability would seem unreliable at best.
The technique basically produces a
single central and peripheral end-point
to determine MPOD. The MPOD
value determined using the Macular
Densitometer by comparison repre-
sents the average of multiple (typically
four to six readings) end-points deter-
mined by the subject. Variation in
performance, or lack of understanding
of the task, becomes immediately
obvious as a large standard deviation
Fig. 4. Bland–Altman plot showing 95% limits of agreement for repeat measures at visit 2 and
visit 3 for the Macular Densitometer.
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in the radiance values produced and
allows the examiner to ensure result
reliability, to a degree that is simply
not achievable with MPS 9000.
The variation in the stimulus-back-
ground configuration between instru-
ments is also substantial and certainly
has the potential to induce measure-
ment discrepancies. For the Macular
Densitometer, the configuration is a
short-wave blue background, against
which an incremental blue target is
viewed. For the MPS 9000, the blue
target is viewed against a spectrally
broadband white light surround.
While it is likely that both configura-
tions effectively suppress the contribu-
tion of rods and S-cones, other HFP
methods, such as those used by Beatty
et al. (2000) and Bone & Sparrock
(1971) which have employed a centre-
surround stimulus configuration, have
been shown to produce a spectral
curve that is best fit with a significant
rod contribution (Hammond et al.
2005). Such a centre-surround config-
uration could potentially suffer retinal
adaptation effects, chromatic aberra-
tion effects, and off-axis lens effects
induced by the +5D focusing lens. It
is simply unclear whether the target-
stimulus configuration, as employed in
the MPS 9000, fulfils the basic princi-
ple of any technique for the measure-
ment of MP, namely that such a
technique ‘should provide spectral
absorption curves that match the
extinction spectra of MP’ (Hammond
et al. 2005).
The current study was designed to
evaluate the comparability and repeat-
ability of MPOD measurements, as
determined using the commercial
MPS 9000 in relation to the conven-
tional research standard Macular
Densitometer. It is important to note
that the experimental protocol was
designed to be of clinical relevance
and was compliant with manufacturer
guidelines. The MPS 9000 appears to
provide an unpredictable underestima-
tion of MPOD when compared to the
Macular Densitometer and demon-
strates poorer repeatability. Our anal-
ysis suggests that the fundamental
principles and technique of the MPS
9000 seem generally robust, but that
the unacceptable test–retest variability
observed here and elsewhere (Bartlett
et al. 2010) may largely be as a conse-
quence of the (i) absence of a user-
friendly means to assess subject
performance variability during the test
procedure, (ii) increased difficulty
associated with the peripheral task
and (iii) dependency on examiner
training and skill level. In the
presence of such design features, we
would recommend that best clinical
practice using the MPS 9000 would
require multiple measures of MPOD.
Results should be discarded where
large discrepancies such as those
obtained by Bartlett et al. (2010) are
found and where results are more
consistent, the average MPOD should
be used.
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